BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2784456)

  • 1. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells.
    Servis C; Lambris JD
    J Immunol; 1989 Apr; 142(7):2207-12. PubMed ID: 2784456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
    Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
    J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
    Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
    Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
    Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
    Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration.
    Tsokos GC; Lambris JD; Finkelman FD; Anastassiou ED; June CH
    J Immunol; 1990 Mar; 144(5):1640-5. PubMed ID: 2137840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CR2 ligands modulate human B cell activation.
    Bohnsack JF; Cooper NR
    J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
    Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
    J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
    Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
    J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3.
    Vĕtvicka V; Reed W; Hoover ML; Ross GD
    J Immunol; 1993 May; 150(9):4052-60. PubMed ID: 8473749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
    Nemerow GR; McNaughton ME; Cooper NR
    J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.
    Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R
    Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
    Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
    J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum regulates the expression of complement receptor 2 on human B cell lines.
    Tolnay M; Tsokos GC
    Immunopharmacol Immunotoxicol; 2000 May; 22(2):205-19. PubMed ID: 10952027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM.
    Carter RH; Fearon DT
    J Immunol; 1989 Sep; 143(6):1755-60. PubMed ID: 2528579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and signalling functions of C3 receptors on human B cells.
    Frade R
    Semin Immunol; 1990 Mar; 2(2):159-64. PubMed ID: 2151800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A complement C3 fragment equivalent to mammalian C3d from the common carp (Cyprinus carpio): generation in serum after activation of the alternative pathway and detection of its receptor on the lymphocyte surface.
    Nakao M; Miura C; Itoh S; Nakahara M; Okumura K; Mutsuro J; Yano T
    Fish Shellfish Immunol; 2004 Feb; 16(2):139-49. PubMed ID: 15123318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.
    Tedder TF; Goldmacher VS; Lambert JM; Schlossman SF
    J Immunol; 1986 Aug; 137(4):1387-91. PubMed ID: 3016095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of C3 and its fragments in the control of S phase entry of activated mouse B lymphocytes via the complement receptor type 2.
    Lernhardt W; Melchers F
    Exp Clin Immunogenet; 1988; 5(2-3):115-22. PubMed ID: 2978811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.